Advertisement

Preventing HIV/AIDS in the United States, 1981–2009: History in the Making

  • Ronald Valdiserri
Chapter

Abstract

The history of HIV/AIDS prevention is, without question, a great, unfinished work. True, there have been important milestones in the three decades since the epidemic was first described in the United States [1]—accomplishments in science, advances in policy and the evolution of organized efforts to prevent the spread of the human immunodeficiency virus [2]. Yet, the epidemic is far from over, either in the United States or elsewhere in the world. According to the UNAIDS, there were 33 million people living with HIV in 2007 and almost 3 million new infections that same year [3]. In the United States, an estimated 56,300 persons became newly infected with HIV in 2006—roughly 40 % higher than previous estimates of HIV incidence [4]. Continued gaps in knowledge, notably in the domains of vaccine and microbicide development, have blunted efforts to prevent continued HIV transmission [5] and failure to bring proven HIV prevention interventions and programs to scale [6] has impeded optimal progress.

Keywords

Injection Drug User Male Circumcision Methadone Maintenance Treatment Injection Drug User Correctional Facility 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Centers for Disease Control and Prevention. Pneumocystis pneumonia—Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30:250–2.Google Scholar
  2. 2.
    Valdiserri RO. HIV/AIDS in historical profile. In: Valdiserri RO, editor. Dawning answers: How the HIV/AIDS epidemic has helped to strengthen public health. Oxford: Oxford University Press; 2003. p. 3–32.Google Scholar
  3. 3.
    UNAIDS. 2008 epidemiology slides. http://data.unaids.org/pub/GlobalReport/2008. Accessed 30 Dec 2008.
  4. 4.
    Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the united states. JAMA. 2008;300:520–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Merson MH, O’Malley J, Serwadda D, Apisuk C. The history and challenge of HIV prevention. Lancet. 2008;372:475–88.PubMedCrossRefGoogle Scholar
  6. 6.
    Global HIV Prevention Working Group. Bringing HIV prevention to scale: an urgent global priority. http://www.globalhivprevention.org/pdfs/PWG-HIV_prevention_report-FINAL.pdf. Accessed 30 Dec 2008.
  7. 7.
    Valdiserri RO. Preventing AIDS: the design of effective programs. New Brunswick, NJ: Rutgers University Press; 1989.Google Scholar
  8. 8.
    Gottlieb MS. AIDS—past and future. N Engl J Med. 2001;344:1788–90.PubMedCrossRefGoogle Scholar
  9. 9.
    Centers for Disease Control and Prevention. HIV prevalence estimates—United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57:1073–6.Google Scholar
  10. 10.
    Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2007, vol. 19. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2009. p. 1–63.Google Scholar
  11. 11.
    Centers for Disease Control and Prevention. A cluster of Kaposi’s sarcoma and Pneumocystis carinii pneumonia among homosexual male residents of Los Angeles and orange counties, California. MMWR Morb Mortal Wkly Rep. 1982;31:305–7.Google Scholar
  12. 12.
    Centers for Disease Control and Prevention. Possible transfusion-associated acquired immune deficiency syndrome (AIDS)—California. MMWR Morb Mortal Wkly Rep. 1982;31:652–4.Google Scholar
  13. 13.
    Centers for Disease Control and Prevention. Prevention of acquired immune deficiency syndrome (AIDS): report of inter-agency recommendations. MMWR Morb Mortal Wkly Rep. 1983;32(8):101–4.Google Scholar
  14. 14.
    Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 1994;5(4):1–33.Google Scholar
  15. 15.
    Hariri S, McKenna MT. Epidemiology of human immunodeficiency virus in the United States. Clin Microbiol Rev. 2007;20:478–88.PubMedCrossRefGoogle Scholar
  16. 16.
    Centers for Disease Control and Prevention. HIV and AIDS—United States, 1981–2000. MMWR Morb Mortal Wkly Rep. 2001;50:430–4.Google Scholar
  17. 17.
    Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220:868–71.PubMedCrossRefGoogle Scholar
  18. 18.
    Lite J. Montagnier, Barre-Sinoussi and zur Hausen Share Nobel. Scientific American, Oct 6 2008. http://www.sciam.com/article.cfm?id=montagnier-barre-sinoussi%26print=true. Accessed 6 Jan 2009.
  19. 19.
    Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984;224:500–3.PubMedCrossRefGoogle Scholar
  20. 20.
    Centers for Disease Control and Prevention. Results of human T-lymphotropic virus type III test kits reported from blood collection centers—United States, April 22–May 19 1985. MMWR Morb Mortal Wkly Rep. 1985;34:375–6.Google Scholar
  21. 21.
    Buehler JW. HIV and AIDS surveillance: public health lessons learned. In: Valdiserri RO, editor. Dawning answers: How the HIV/AIDS epidemic Has helped to strengthen public health. Oxford, England: Oxford University Press; 2003. p. 33–55.Google Scholar
  22. 22.
    Coffin J, Haase A, Levy JA, et al. Human immunodeficiency viruses. Science. 1986;232:697.PubMedCrossRefGoogle Scholar
  23. 23.
    Klevens RN, Hughes D. The impact of transfusion-associated AIDS in the United States. Abstract 769-W. 9th Conference on Retroviruses and Opportunistic Infections. 2002. http://www.retroconference.org/2002/Abstract/13540.htm. Accessed 21 Jan 2009.
  24. 24.
    Selik RM, Ward JW, Buehler JW. Trends in transfusion-associated acquired immune deficiency syndrome in the United States, 1982 through 1991. Transfusion. 1993;33:890–3.PubMedCrossRefGoogle Scholar
  25. 25.
    Gwinn M, Pappaioanou M, George RJ, et al. Prevalence of HIV infection in childbearing women in the United States: surveillance using newborn blood samples. JAMA. 1991;265:1704–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Centers for Disease Control and Prevention. National HIV serosurveillance summary: results through 1992, vol. 3. Atlanta, GA: U.S. Department of Health and Human Services; 1994.Google Scholar
  27. 27.
    Centers for Disease Control and Prevention. Zidovudine for the prevention of HIV transmission from mother to infant. MMWR Morb Mortal Wkly Rep. 1994;43:285–7.Google Scholar
  28. 28.
    Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173–80.PubMedCrossRefGoogle Scholar
  29. 29.
    Centers for Disease Control and Prevention. Recommendations for the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1994;43(No. RR-11):1–20.Google Scholar
  30. 30.
    Centers for Disease Control and Prevention. U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR Morb Mortal Wkly Rep. 1995;44(No. RR-7):1–15.Google Scholar
  31. 31.
    Centers for Disease Control and Prevention. Recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 1985;34(48):721–32.Google Scholar
  32. 32.
    Lindegren ML, Byers RH, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA. 1999;282:531–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Institute of Medicine, Committee on Perinatal Transmission of HIV. Reducing the odds: preventing perinatal transmission of HIV in the United States. Washington, DC: National Academy Press; 1999.Google Scholar
  34. 34.
    Centers for Disease Control and Prevention. Achievements in public health: reduction in perinatal transmission of HIV infection—United States, 1985—2005. MMWR Morb Mortal Wkly Rep. 2006;55(21):592–7.Google Scholar
  35. 35.
    Centers for Disease Control and Prevention. Update: trends in AIDS incidence, deaths, and prevalence—United States, 1996. MMWR Morb Mortal Wkly Rep. 1997;46(8):165–73.Google Scholar
  36. 36.
    Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853–60.PubMedCrossRefGoogle Scholar
  37. 37.
    Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293–9.CrossRefGoogle Scholar
  38. 38.
    Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984–1997. JAMA. 2001;285(10):1308–15.PubMedCrossRefGoogle Scholar
  39. 39.
    Janssen RS, Valdiserri RO. HIV prevention in the United States: increasing emphasis on working with those living with HIV. J Acquir Immune Defic Syndr. 2004;37(2):S119–21.PubMedCrossRefGoogle Scholar
  40. 40.
    Centers for Disease Control and Prevention. Subpopulation estimates from the HIV incidence surveillance system—United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57(36):985–9.Google Scholar
  41. 41.
    Valdiserri RO. Technology transfer: achieving the promise of HIV prevention. In: Peterson JL, DiClemente RJ, editors. Handbook of HIV prevention. New York, NY: Kluwer Academic/Plenum; 2000. p. 267–83.CrossRefGoogle Scholar
  42. 42.
    Centers for Disease Control and Prevention. Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men—New York city and California. MMWR Morb Mortal Wkly Rep. 1981;30:305–8.Google Scholar
  43. 43.
    Centers for Disease Control and Prevention. Follow-up on Kapposi’s sarcoma and Pneumocystis pneumonia. MMWR Morb Mortal Wkly Rep. 1981;30:409–10.Google Scholar
  44. 44.
    Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305(24):1431–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Centers for Disease Control and Prevention. Unexplained immunodeficiency and opportunistic infections in infants—New York, New Jersey, California. MMWR Morb Mortal Wkly Rep. 1982;31:665–7.Google Scholar
  46. 46.
    Andriote JM. Victory deferred: how AIDS changed Gay life in America. Chicago, IL: University of Chicago Press; 1999.Google Scholar
  47. 47.
    Leo J. The real epidemic: fear and despair: AIDS isolates many of its victims and is changing the gay life-style. Time Magazine. July 4; 1983. pp. 56–8.Google Scholar
  48. 48.
    Kinsella J. Covering the plague. New Brunswick, NJ: Rutgers University Press; 1989.Google Scholar
  49. 49.
    Thomas E. The new untouchables: anxiety over AIDS is verging on hysteria in some parts of the country. Time Magazine, 23 Sep 1985. pp. 24–26.Google Scholar
  50. 50.
    Centers for Disease Control and Prevention. Acquired immune deficiency syndrome (AIDS): precautions for clinical and laboratory staffs. MMWR Morb Mortal Wkly Rep. 1982;31:577–80.Google Scholar
  51. 51.
    Centers for Disease Control and Prevention. Antibodies to a retrovirus etiologically associated with acquired immunodeficiency syndrome (AIDS) in populations with increased incidences of the syndrome. MMWR Morb Mortal Wkly Rep. 1984;33:377–9.Google Scholar
  52. 52.
    Centers for Disease Control and Prevention. Provisional public health service inter-agency recommendations for screening donated blood and plasma for antibody to the virus causing acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 1985;34:1–5.Google Scholar
  53. 53.
    Mason JO. Public health service plan for the prevention and control of acquired immune deficiency syndrome (AIDS). Public Health Rep. 1985;100(5):453–5.Google Scholar
  54. 54.
    American Public Health Association. Criteria for the development of health promotion and education programs. Am J Public Health. 1987;77:89–92.CrossRefGoogle Scholar
  55. 55.
    Research and Decisions Corporation. Designing an effective AIDS prevention campaign strategy for San Francisco: Results from the first probability sample of an Urban Gay Male Community. 3 Dec 1984, San Francisco, CA.Google Scholar
  56. 56.
    McKusick L, Horstman W, Coates TJ. AIDS and sexual behavior reported by Gay men in San Francisco. Am J Public Health. 1985;75:493–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Wohlfeiler D. Community organizing and community building among Gay and bisexual Men. In: Minkler M, editor. Community organizing and community building for health. New Brunswick, NJ: Rutgers University Press; 1997. p. 230–43.Google Scholar
  58. 58.
    Centers for Disease Control and Prevention. Evolution of HIV/AIDS prevention programs—United States, 1981–2006. MMWR Morb Mortal Wkly Rep. 2006;55:597–603.Google Scholar
  59. 59.
    Bailey ME. Community-based organizations and CDC as partners in HIV education and prevention. Public Health Rep. 1991;106:702–8.PubMedGoogle Scholar
  60. 60.
    Arno PS. The nonprofit sector’s response to the AIDS epidemic: community-based services in San Francisco. Am J Public Health. 1986;76:1325–30.PubMedCrossRefGoogle Scholar
  61. 61.
    Palacios-Jimenez SM. Facilitator’s guide to eroticizing safer sex: a psychoeducational workshop approach to safer sex education. New York: Gay Men’s Health Crisis; 1986.Google Scholar
  62. 62.
    Booth W. Another muzzle for AIDS education? Science. 1987;238:1036.PubMedCrossRefGoogle Scholar
  63. 63.
    Kolata G. Erotic films in AIDS study cut risky behavior. New York Times, 3 Nov 1987. p. 18.Google Scholar
  64. 64.
    Johnson JA. AIDS funding for federal government programs: FY1981—FY2009. Congressional Research Service. 23 Apr 2008. http://assets.opencrs.com/rpts/RL30731_20080423.pdf. Accessed 4 Mar 2009.
  65. 65.
    Fineberg HV. Education to prevent AIDS: prospects and obstacles. Science. 1988;239:592–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Centers for Disease Control and Prevention. Content of AIDS-related materials, pictorials, audiovisuals, questionnaires, survey instruments, and educational sessions in Centers for Disease Control and Prevention (CDC) assistance programs. http://www.cdc.gov/od/pgo/forms/hiv.htm. Accessed 4 Mar 2009.
  67. 67.
    U.S. Public Health Service Executive Task Force on AIDS. Coolfont report: a PHS plan for prevention and control of AIDS and the AIDS virus. Public Health Rep. 1986;101:341–8.Google Scholar
  68. 68.
    Hartgers C, Ameijden EJ, Hoek JA, Coutinho RA. Needle sharing and participation in the Amsterdam Syringe Exchange Program among HIV-seronegative injecting drug users. Public Health Rep. 1992;107:675–81.PubMedGoogle Scholar
  69. 69.
    Strathdee SA, Vlahov D. The effectiveness of needle exchange programs: a review of the science and policy. AIDScience. 2001; 1(16). http://aidscience.org/Articles/aidscience013.12p. Accessed 12 Mar 2009.
  70. 70.
    Gostin LO. The legal environment impeding access to sterile syringes and needles: the conflict between law enforcement and public health. J Acquir Immune Defic Syndr. 1998;18 Suppl 1:S60–70.Google Scholar
  71. 71.
    Lane SD. A brief history. In: Stryker J, Smith M, editors. Dimensions of HIV prevention: needle exchange. Menlo Park, CA: Henry J. Kaiser Family Foundation; 1993. p. 1–9.Google Scholar
  72. 72.
    Thomas SB, Quinn SC. The burdens of race and history on Black Americans’ attitudes toward needle exchange policy to prevent HIV disease. J Public Health Policy. 1993;14:320–47.PubMedCrossRefGoogle Scholar
  73. 73.
    Committee on the Prevention of HIV Infection among Injection Drug Users in High Risk Countries. Preventing HIV infection among injecting drug users in high-risk countries: an assessment of the evidence. Washington, DC: National Academies Press; 2007.Google Scholar
  74. 74.
    Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;4(1):777–813.CrossRefGoogle Scholar
  75. 75.
    Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet. 1997;349:1797–800.PubMedCrossRefGoogle Scholar
  76. 76.
    Des Jarlais DC, Hagan H, Friedman SR, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA. 1995;274:1226–31.PubMedCrossRefGoogle Scholar
  77. 77.
    Centers for Disease Control and Prevention. Syringe exchange programs—United States, 2005. MMWR Morb Mortal Wkly Rep. 2007;56:1164–7.Google Scholar
  78. 78.
    Schwartzapfel B. Swapping politics for science on drug policy. The Nation. 12/21/2009. http://www.thenation.com/doc/20100104/schwartzapfel/print. Accessed on 3 Mar 2010.
  79. 79.
    Centers for Disease Control and Prevention. Impact of new legislation on needle and syringe purchase and possession—Connecticut, 1992. MMWR Morb Mortal Wkly Rep. 1993;42:145–8.Google Scholar
  80. 80.
    Valleroy LA, Weinstein B, Jones TS, Groseclose SL, Rolfs RT, Kassler WJ. Impact of increased legal access to needles and syringes on community pharmacies’ needle and syringe sales—Connecticut, 1992–1993. J Acquir Immune Defic Syndr. 1995;10:73–81.Google Scholar
  81. 81.
    Groseclose SL, Weinstein B, Jones TS, Valleroy LA, Fehrs LJ, Kassler WJ. Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officers—Connecticut, 1992–1993. J Acquir Immune Defic Syndr. 1995;10:82–9.Google Scholar
  82. 82.
    Compton WM, Horton JC, Cottler LB, et al. A multistate trial of pharmacy syringe purchase. J Urban Health. 2004;81:661–70.PubMedCrossRefGoogle Scholar
  83. 83.
    Deibert RJ, Goldbaum G, Parker TR, et al. Increased access to unrestricted pharmacy sales of syringes in Seattle-king county, Washington: structural and individual-level changes, 1996 versus 2003. Am J Public Health. 2006;96:1347–53.PubMedCrossRefGoogle Scholar
  84. 84.
    Fuller CM, Galea S, Caceres W, Blaney S, Sisco S, Vlahov D. Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York city. Am J Public Health. 2007;97:117–24.PubMedCrossRefGoogle Scholar
  85. 85.
    Gibson DR, Flynn NM, McCarthy JJ. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 1999;13:1807–18.PubMedCrossRefGoogle Scholar
  86. 86.
    Williams AB, McNelly EA, Williams AE, D’Aquila RT. Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users. AIDS Care. 1992;4:35–41.PubMedCrossRefGoogle Scholar
  87. 87.
    Metzger DS, Woody GE, McLellan T. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18 month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6:1049–56.PubMedGoogle Scholar
  88. 88.
    Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention. Public Health Rep. 1998;113 Suppl 1:97–106.PubMedGoogle Scholar
  89. 89.
    Kleber HD. Methadone maintenance 4 decades later: thousands of lives saved but still controversial. JAMA. 2008;300:2303–5.PubMedCrossRefGoogle Scholar
  90. 90.
    Des Jarlais DC, Paone D, Friedman SR, Peyser N, Newman RG. Regulating controversial programs for unpopular people: methadone maintenance and syringe exchange programs. Am J Public Health. 1995;85:1577–84.PubMedCrossRefGoogle Scholar
  91. 91.
    Centers for Disease Control and Prevention. HIV diagnoses among injection-drug users in states with HIV surveillance—25 States, 1994–2000. MMWR Morb Mortal Wkly Rep. 2003;52:634–6.Google Scholar
  92. 92.
    Centers for Disease Control and Prevention. Trends in HIV/AIDS diagnoses—33 states, 2001–2004. MMWR Morb Mortal Wkly Rep. 2005;54:1149–53.Google Scholar
  93. 93.
    Des Jarlais DC, Marmor M, Friedmann P, et al. HIV incidence among injection drug users in New York city, 1992–1997: evidence for a declining epidemic. Am J Public Health. 2000;90:352–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Des Jarlais DC, Arasteh K, Perlis T, et al. Converging of HIV seroprevalence among injecting and non-injecting drug users in New York city. AIDS. 2007;21:231–5.PubMedCrossRefGoogle Scholar
  95. 95.
    Brandt A. AIDS in historical perspective: four lessons from the history of sexually transmitted diseases. Am J Public Health. 1988;78:367–71.PubMedCrossRefGoogle Scholar
  96. 96.
    Brandt A. No magic bullet: a social history of venereal disease in the United States since 1880. New York, NY: Oxford University Press; 1985.Google Scholar
  97. 97.
    Institute of Medicine, Committee on a National Strategy for AIDS. Confronting AIDS: directions for public health, health care and research. Washington, DC: National Academy Press; 1986.Google Scholar
  98. 98.
    Valdiserri RO. Epidemics in perspective. J Med Humanit Bioeth. 1987;8:95–100.PubMedCrossRefGoogle Scholar
  99. 99.
    Kosterlitz J. Educating about AIDS. Natl J Aug 30, 1986; 35:2044–9.Google Scholar
  100. 100.
    Woods D, David D, Westover FJ. “America Responds to AIDS:” its content, process and outcome. Public Health Rep. 1991;106:616–22.PubMedGoogle Scholar
  101. 101.
    Keiser NH. Strategies of media marketing for “American Responds to AIDS” and applying lessons learned. Public Health Rep. 1991;106:623–7.PubMedGoogle Scholar
  102. 102.
    Centers for Disease Control and Prevention. Understanding AIDS: an information brochure being mailed to all U.S. households. MMWR Morb Mortal Wkly Rep. 1988;37:261–9.Google Scholar
  103. 103.
    Mason JO, Noble GR, Lindsey BK, et al. Current CDC efforts to prevent and control human immunodeficiency virus infection and AIDS in the United States through information and education. Public Health Rep. 1988;103:255–60.PubMedGoogle Scholar
  104. 104.
    Centers for Disease Control and Prevention. Guidelines for effective school health education to prevent the spread of AIDS. MMWR Morb Mortal Wkly Rep. 1988;37(S-2):1–14.Google Scholar
  105. 105.
    Office of Technology Assessment, U.S. Congress. Review of the public health service’s response to AIDS. Washington, DC: U.S. Congress Office of Technology Assessment, OTA-TM-H-24; February 1985.Google Scholar
  106. 106.
    Panem S. The AIDS bureaucracy. Cambridge, MA: Harvard University Press; 1988.Google Scholar
  107. 107.
    Institute of Medicine. The AIDS Research Program of the National Institutes of Health. Washington, DC: National Academies Press; 1991.Google Scholar
  108. 108.
    U.S. General Accounting Office. AIDS Education: Reaching Populations at Higher Risk; Report to the Chairman, Committee on Governmental Affairs, U.S. Senate. Washington, DC: U.S. General Accounting Office; September 1988 (PEMD-88-35).Google Scholar
  109. 109.
    Lorig K, Laurin J. Some notions about assumptions underlying health education. Health Educ Q. 1985;12:231–43.PubMedCrossRefGoogle Scholar
  110. 110.
    McGinnis JM. Recent history of federal initiatives in prevention policy. Am Psychol. 1985;40:205–12.PubMedCrossRefGoogle Scholar
  111. 111.
    Minkler M. Health education, health promotion and the open society: an historical perspective. Health Educ Q. 1989;16:17–30.PubMedCrossRefGoogle Scholar
  112. 112.
    Leviton LC. Theoretical foundations of AIDS-prevention programs. In: Valdiserri RO, editor. Preventing AIDS: the design of effective programs. New Burnswick, NJ: Rutgers University Press; 1989.Google Scholar
  113. 113.
    Centers for Disease Control and Prevention. Compendium of HIV prevention interventions with evidence of effectiveness, March 1999:1–57. http://www.cdc.gov/resources/reports/hiv_compendium/index.htm. Accessed 24 Mar 2009.
  114. 114.
    Kelly JA, Lawrence JS, Hood HV, Brasfield TL. Behavioral intervention to reduce AIDS risk activities. J Consult Clin Psychol. 1989;57:60–7.PubMedCrossRefGoogle Scholar
  115. 115.
    Valdiserri RO, Lyter DW, Leviton LC, Callahan CM, Kingsley LA, Rinaldo CR. AIDS prevention in homosexual and bisexual men: results of a randomized trial evaluating two risk reduction interventions. AIDS. 1989;3:21–6.PubMedGoogle Scholar
  116. 116.
    Institute of Medicine. Confronting AIDS: update 1988. Washington, DC: National Academy Press; 1988.Google Scholar
  117. 117.
    Turner CF, Miller HG, Moses LE, editors. AIDS: sexual behavior and intravenous drug Use. Washington, DC: National Academy Press; 1989.Google Scholar
  118. 118.
    Miller HG, Turner CF, Moses LE, editors. AIDS: the second decade. Washington, DC: National Academy Press; 1990.Google Scholar
  119. 119.
    Coyle SL, Boruch RF, Turner CF, editors. Evaluating AIDS Prevention Programs: expanded edition. Washington, DC: National Academy Press; 1991.Google Scholar
  120. 120.
    Kelly JA, Murphy DA, Sikkema KJ, Kalichman SC. Psychological interventions to prevent HIV infection are urgently needed: new priorities for behavioral research in the second decade of AIDS. Am Psychol. 1993;48:1023–34.PubMedCrossRefGoogle Scholar
  121. 121.
    Auerbach JD, Wypijewska C, Brodie HK, editors. AIDS and behavior: an integrated approach. Washington, DC: National Academy Press; 1994.Google Scholar
  122. 122.
    Higgins DL, Galavotti C, O’Reilly K, Sheridan J. Evolution and development of the aids community demonstration projects. In: Corby NH, Wolitski RJ, editors. Community HIV prevention: the Long Beach AIDS Community Demonstration Projects. Long Beach, CA: California State University Press; 1997. p. 5–20.Google Scholar
  123. 123.
    O’Reilly KR, Higgins DL. AIDS Community Demonstration Projects for HIV prevention among hard-to-reach groups. Public Health Rep. 1991;106:714–20.PubMedGoogle Scholar
  124. 124.
    Centers for Disease Control and Prevention. Community-level prevention of human immunodeficiency virus infection among high-risk populations: The AIDS Community Demonstration Projects. MMWR Morb Mortal Wkly Rep. 1996;45(RR-6):1–24.Google Scholar
  125. 125.
    CDC AIDS Community Demonstration Projects Research Group. Community-level HIV intervention in 5 cities: final outcome data from the CDC AIDS Community Demonstration Projects. Am J Public Health. 1999;89:336–45.CrossRefGoogle Scholar
  126. 126.
    Centers for Disease Control and Prevention, National Institutes of Health, Center for Substance Abuse Treatment. Statement on the role of bleach in HIV prevention programs for injecting drug users (IDUs). 5 May 1993. http://www.aegis.com/pubs/Cdc_Fact_Sheets/1993/CDC93150.html. Accessed 4 Feb 2009.
  127. 127.
    Kirby D, Barth RP, Leland N, Fetro JV. Reducing the risk: impact of a new curriculum on sexual risk-taking. Fam Plann Perspect. 1991;23:253–63.PubMedCrossRefGoogle Scholar
  128. 128.
    Jemmott JB, Jemmott LS, Fong GT. Reductions in HIV risk-associated sexual behaviors among black male adolescents: effects of an AIDS prevention intervention. Am J Public Health. 1992;82:372–7.PubMedCrossRefGoogle Scholar
  129. 129.
    St. Lawrence JS, Brasfield TL, Jefferson KW, Alleyne E, O’Bannon RE, Shirley A. Cognitive-behavioral intervention to reduce African American adolescents’ risk for HIV infection. J Consult Clin Psychol. 1995;63:221–37.PubMedCrossRefGoogle Scholar
  130. 130.
    Jemmott JB, Jemmott LS, Fong GT. Abstinence and safer sex HIV risk-reduction interventions for African American adolescents. JAMA. 1998;279:1529–36.PubMedCrossRefGoogle Scholar
  131. 131.
    DesJarlais DC, Casriel C, Friedman SR, Rosenblum A. AIDS and the transition to illicit drug injection—results of a randomized trial prevention program. Br J Addict. 1992;87:493–8.CrossRefGoogle Scholar
  132. 132.
    McCusker J, Stoddard AM, Zapka JG, Morrison CS, Zorn M, Lewis BF. AIDS education for drug abusers: evaluation of short-term effectiveness. Am J Public Health. 1992;82:533–40.PubMedCrossRefGoogle Scholar
  133. 133.
    El-Bassel N, Schilling RF. 15 month followup of women methadone patients taught skills to reduce heterosexual HIV transmission. Public Health Rep. 1992;107:500–4.PubMedGoogle Scholar
  134. 134.
    Siegal HA, Falck RS, Carlson RG, Wang J. Reducing HIV needle risk behaviors among injection-drug users in the midwest: an evaluation of the efficacy of standard and enhanced interventions. AIDS Educ Prev. 1995;7:308–19.PubMedGoogle Scholar
  135. 135.
    Kelly JA, St. Lawrence JS, Stevenson Y, et al. Community AIDS/HIV risk reduction: the effects of endorsements by popular people in three cities. Am J Public Health. 1992;82:1483–9.PubMedCrossRefGoogle Scholar
  136. 136.
    Kegeles SM, Hays RB, Coates TJ. The Mpowerment Project: a community-level HIV prevention intervention for young gay men. Am J Public Health. 1996;86:1129–36.PubMedCrossRefGoogle Scholar
  137. 137.
    Kelly JA, Murphy DA, Washington CD, et al. The effects of HIV/AIDS intervention groups for high-risk women in urban clinics. Am J Public Health. 1994;84:1918–22.PubMedCrossRefGoogle Scholar
  138. 138.
    DiClemente RJ, Wingood GM. A randomized controlled trial of an HIV sexual risk-reduction intervention for young African-American women. JAMA. 1995;274:1271–6.PubMedCrossRefGoogle Scholar
  139. 139.
    Lauby JL, Smith PJ, Stark M, Person B, Adams J. A community-level HIV prevention intervention for inner-city women: results of the women and infants demonstration projects. Am J Public Health. 2000;90:216–22.PubMedCrossRefGoogle Scholar
  140. 140.
    Watkins JD. Report of the presidential commission on the human immunodeficiency virus epidemic. Washington, DC: U.S. Government Printing Office; 1988.Google Scholar
  141. 141.
    Osborn JE. AIDS: an expanding tragedy: the final report of the National Commission on AIDS. Washington, DC: U.S. Government Printing Office; 1993.Google Scholar
  142. 142.
    Bleakley A, Hennessy M, Fishbein M. Public opinion on sex education in US schools. Arch Pediatr Adolesc Med. 2006;160:1151–6.PubMedCrossRefGoogle Scholar
  143. 143.
    Darroch JE, Landry DJ, Singh S. Changing emphases in sexuality education in U.S. Public Secondary Schools, 1988–1999. Fam Plann Perspect. 2000;32:204–11. & 265.PubMedCrossRefGoogle Scholar
  144. 144.
    Landry DJ, Darroch JE, Singh S, Higgins J. Factors associated with the contents of sex education in U.S. public secondary schools. Perspect Sex Reprod Health. 2003;35:261–9.PubMedCrossRefGoogle Scholar
  145. 145.
    Lindau ST, Tetteh AS, Kasza K, Gilliam M. What schools teach our patients about sex: content, quality and influences on sex education. Obstet Gynecol. 2008;111:256–66.PubMedCrossRefGoogle Scholar
  146. 146.
    O’Donnell L, O’Donnell CR, Stueve A. Early sexual initiation and subsequent sex-related risks among urban minority youth: the reach for health study. Fam Plann Perspect. 2001;33:268–75.PubMedCrossRefGoogle Scholar
  147. 147.
    Resnick MD, Blum RW. The association of consensual sexual intercourse during childhood with adolescent health risk and behaviors. Pediatrics. 1994;94:907–13.PubMedGoogle Scholar
  148. 148.
    Santelli J, Ott MA, Lyon M, Rogers J, Summers D, Schleifer R. Abstinence and abstinence-only education: a review of U.S. policies and programs. J Adolesc Health. 2006;38:72–81.PubMedCrossRefGoogle Scholar
  149. 149.
    Society for Adolescent Medicine. Abstinence-only education policies and programs: a position paper of the Society for Adolescent Medicine. J Adolesc Health. 2006;38:83–7.CrossRefGoogle Scholar
  150. 150.
    Kirby DB. The impact of abstinence and comprehensive sex and STD/HIV education programs on adolescent sexual behavior. Sex Res Soc Policy. 2008;5:18–27.CrossRefGoogle Scholar
  151. 151.
    Robin L, Dittus P, Whitaker D, et al. Behavioral interventions to reduce incidence of HIV, STD, and pregnancy among adolescents: a decade in review. J Adolesc Health. 2004;34:3–26.PubMedCrossRefGoogle Scholar
  152. 152.
    Kann L, Telljohann SK, Wooley SF. Health education: results from the school health policies and programs study 2006. J School Health. 2007;77:408–34.PubMedCrossRefGoogle Scholar
  153. 153.
    Centers for Disease Control and Prevention. Trends in HIV- and STD-related risk behaviors among high school students—United States, 1991–2007. MMWR Morb Mortal Wkly Rep. 2008;57:817–22.Google Scholar
  154. 154.
    Centers for Disease Control and Prevention. Acquired immunodeficiency syndrome in correctional facilities: a report of the National Institute of Justice and the American Correctional Association. MMWR Morb Mortal Wkly Rep. 1986;35:195–9.Google Scholar
  155. 155.
    Valdiserri EV, Hartl AJ, Chamblis CA. Practices reported by incarcerated drug abusers to reduce risk of AIDS. Hosp Community Psychiatry. 1988;39:966–72.PubMedGoogle Scholar
  156. 156.
    Schilling R, El-Bassel N, Ivanoff A, Gilbert L, Su KH, Safyer SM. Sexual risk behavior of incarcerated, drug-using women, 1992. Public Health Rep. 1994;109:539–47.PubMedGoogle Scholar
  157. 157.
    Brewer TF, Vlahov D, Taylor E, Hall D, Munoz A, Polk BF. Transmission of HIV-1 within a statewide prison system. AIDS. 1988;2:363–7.PubMedCrossRefGoogle Scholar
  158. 158.
    Braithwaite RL, Hammett RM, Mayberry RM. Prisons and AIDS: a public health challenge. San Francisco, CA: Jossey-Bass Publishers; 1996.Google Scholar
  159. 159.
    Centers for Disease Control and Prevention. HIV transmission among male inmates in a state prison system—Georgia, 1992—2005. MMWR Morb Mortal Wkly Rep. 2006;55:421–6.Google Scholar
  160. 160.
    National Commission on AIDS. HIV disease in correctional facilities. Washington, DC: National Commission on AIDS; 1991.Google Scholar
  161. 161.
    Brewer TF, Derrickson J. AIDS in prison: a review of epidemiology and preventive policy. AIDS. 1992;6:623–8.PubMedCrossRefGoogle Scholar
  162. 162.
    Polonsky S, Kerr S, Harris B, Gaiter J, Fichtner RR, Kennedy MG. HIV prevention in prisons and jails: obstacles and opportunities. Public Health Rep. 1994;109:615–25.PubMedGoogle Scholar
  163. 163.
    May JP, Williams EL. Acceptability of condom availability in a U.S. Jail. AIDS Educ Prev. 2002;14(Suppl B):85–91.PubMedCrossRefGoogle Scholar
  164. 164.
    Hammett TM, Gaiter JL, Crawford C. Reaching seriously at-risk populations: health interventions in criminal justice settings. Health Educ Behav. 1998;25:99–120.PubMedCrossRefGoogle Scholar
  165. 165.
    Jurgens R, Ball A, Verster A. Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis. 2009;9:57–66.PubMedCrossRefGoogle Scholar
  166. 166.
    National Institutes of Health Consensus Development Panel. The impact of routine HTLV-III antibody testing on public health. In: NIH Consensus Develop Conf Statement, 7–9 Jul. Vol 6(5); 1986.Google Scholar
  167. 167.
    Centers for Disease Control and Prevention. Human T-lymphotropic virus type III/ lymphadenopathy-associated virus antibody testing at alternate sites. MMWR Morb Mortal Wkly Rep. 1986;35:284–7.Google Scholar
  168. 168.
    Valdiserri RO. HIV counseling and testing: its evolving role in HIV prevention. AIDS Educ Prev. 1997;9(Suppl B):2–13.PubMedGoogle Scholar
  169. 169.
    Centers for Disease Control and Prevention. Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/ lymphadenopathy-associated virus. MMWR Morb Mortal Wkly Rep. 1986;35:152–5.Google Scholar
  170. 170.
    Centers for Disease Control and Prevention. Public Health Service guidelines for counseling and antibody testing to prevent HIV infection and AIDS. MMWR Morb Mortal Wkly Rep. 1987;36:509–15.Google Scholar
  171. 171.
    Wasserheit JN, Valdiserri RO, Wood RW. Assessment of STD/HIV prevention programs in the United States: national, local, and community perspectives. In: Holmes KK, Sparling PF, Mardh PA, Lemon SM, Stamm WE, Piot P, Wasserheit JN, editors. Sexually transmitted diseases. New York, NY: McGraw-Hill; 1999. p. 1255–71.Google Scholar
  172. 172.
    Holtgrave DR, Qualls NL, Curran JW, Valdiserri RO, Guinan ME, Parra WC. An overview of the effectiveness and efficiency of HIV prevention programs. Public Health Rep. 1995;110:134–46.PubMedGoogle Scholar
  173. 173.
    U.S. General Accounting Office. AIDS Prevention Programs: high-risk groups still prove hard to reach. Washington, DC: U.S. General Accounting Office; 1991. HRD-91-52.Google Scholar
  174. 174.
    American Public Health Association. Special initiative on AIDS. HIV antibody testing. Washington, DC: American Public Health Association; 1989. p. 1–14.Google Scholar
  175. 175.
    Higgins DL, Galavotti C, O’Reilly KR, et al. Evidence for the effects of HIV antibody counseling and testing on risk behavior. JAMA. 1991;266:2419–29.PubMedCrossRefGoogle Scholar
  176. 176.
    Weinhardt LS, Carey MP, Johnson BT, Bickham NL. Effects of HIV counseling and testing on sexual behavior: a meta-analytic review of published research, 1985–1997. Am J Public Health. 1999;89:1397–405.PubMedCrossRefGoogle Scholar
  177. 177.
    Centers for Disease Control and Prevention. Technical guidance on HIV Counseling. MMWR Morb Mortal Wkly Rep. 1993;42(RR-2):8–17.Google Scholar
  178. 178.
    Kamb ML, Fishbein M, Douglas JM, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. JAMA. 1998;280:1161–7.PubMedCrossRefGoogle Scholar
  179. 179.
    Valdiserri RO, Aultman TV, Curran JW. Community planning: a national strategy to improve HIV prevention programs. J Community Health. 1995;20:87–100.PubMedCrossRefGoogle Scholar
  180. 180.
    Holtgrave DR, Valdiserri RO. Year one of HIV prevention community planning: a national perspective on accomplishments, challenges and future directions. J Public Health Manag Pract. 1996;2:1–9.PubMedGoogle Scholar
  181. 181.
    AIDS Action Foundation. A blueprint for reforming federal AIDS prevention programs. Washington, DC: AIDS Action Foundation; 1993. p. 1–26.Google Scholar
  182. 182.
    Association of State and Territorial Health Officials, Council of State and Territorial Epidemiologists, National Alliance of State and Territorial AIDS Directors. State health agency vision for HIV prevention. Washington, DC: Association of State and Territorial Health Officials; 1993. p. 1–10.Google Scholar
  183. 183.
    Office of Technology Assessment. External review of the federal centers for disease control and prevention’s HIV prevention programs: summary and overview. Washington, DC: Office of Technology Assessment; 1994. p. 1–25.Google Scholar
  184. 184.
    Holtgrave DR. Setting priorities and community planning for HIV-prevention programs. AIDS Public Policy. 1994;9:145–51.Google Scholar
  185. 185.
    Kelly J, Effective HIV. Prevention community planning: an assessment of state initiatives. Washington, DC: National Alliance of State and Territorial AIDS Directors; 1994. p. 1–25.Google Scholar
  186. 186.
    Schietinger H, Coburn J, Levi J. Community planning for HIV prevention: findings from the first year. AIDS Public Policy. 1995;10:140–7.Google Scholar
  187. 187.
    Holtgrave DR, Harrison J, Gerber RA, Aultman TV, Scarlett M. Methodological issues in evaluating HIV prevention community planning. Public Health Rep. 1996;111:108–14.PubMedGoogle Scholar
  188. 188.
    Collins C, Franks P. Improving the use of behavioral research in CDC’s HIV prevention community planning process. San Francisco, CA: Center for AIDS Prevention Studies, University of California San Francisco; 1996. p. 1–17.Google Scholar
  189. 189.
    Valdiserri RO. Managing system-wide change in HIV prevention programs: a CDC perspective. Public Admin Rev. 1996;56:545–53.CrossRefGoogle Scholar
  190. 190.
    Bau I. Asians and Pacific islanders and HIV prevention community planning. AIDS Educ Prev. 1998;10(Suppl A):77–93.PubMedGoogle Scholar
  191. 191.
    Valdiserri RO, Robinson C, Lin LS, West GR, Holtgrave DR. Determining allocations for HIV prevention interventions: assessing a change in Federal Funding Policy. AIDS Public Policy. 1997;12:138–48.Google Scholar
  192. 192.
    Kreuter MW. PATCH: its origin, basic concepts, and links to contemporary public health policy. J Health Educ. 1992;23:135–9.Google Scholar
  193. 193.
    Jenkins RA, Carey JW. Decision making for HIV prevention planning: organizational considerations and influencing factors. AIDS Behav. 2005;9:S1–8.PubMedCrossRefGoogle Scholar
  194. 194.
    Jenkins RA, Averbach AR, Robbins A, et al. Improving the use of data for HIV prevention decision making: lessons learned. AIDS Behav. 2005;9:S87–99.PubMedCrossRefGoogle Scholar
  195. 195.
    Mejia R, Jenkins RA, Carey JW, et al. Longitudinal observation of an HIV prevention community planning group (CPG). Health Promot Pract. 2009;10:136–43.PubMedCrossRefGoogle Scholar
  196. 196.
    Freudenberg N, Lee J, Silver D. How Black and Latino community organizations respond to the AIDS epidemic: a case study in One New York city neighborhood. AIDS Educ Prev. 1989;1:12–21.PubMedGoogle Scholar
  197. 197.
    Valdiserri RO, West GR, Moore M, Darrow WW, Hinman AR. Structuring HIV prevention service delivery systems on the basis of social science theory. J Community Health. 1992;17:259–69.PubMedCrossRefGoogle Scholar
  198. 198.
    Freudenberg N, Trinidad U. The role of community organizations in AIDS prevention in two Latino communities in New York city. Health Educ Q. 1992;19:219–32.PubMedCrossRefGoogle Scholar
  199. 199.
    Chillag K, Bartholow K, Cordeiro J, et al. Factors affecting the delivery of HIV/AIDS prevention programs by community-based organizations. AIDS Educ Prev. 2002;14(Suppl A):27–37.PubMedCrossRefGoogle Scholar
  200. 200.
    DiFranceisco W, Kelly JA, Otto-Salaj L, et al. Factors influencing attitudes within aids service organizations toward the use of research-based HIV prevention interventions. AIDS Educ Prev. 1999;11:72–86.PubMedGoogle Scholar
  201. 201.
    Somlai AM, Kelly JA, Otto-Salaj L, et al. Current HIV prevention activities for women and Gay men among 77 ASOs. J Public Health Manag Pract. 1999;5:23–33.PubMedGoogle Scholar
  202. 202.
    Freudenberg N, Eng E, Flay B, Parcel G, Rogers T, Wallerstein N. Strengthening individual and community capacity to prevent disease and promote health: in search of relevant theories and principles. Health Educ Q. 1995;22:290–306.PubMedCrossRefGoogle Scholar
  203. 203.
    Walsh C, Campbell C, Willingham M. HIV/STD prevention program assessments, U.S. Abstract PO-D36-4382. IX International Conference on AIDS. 6–11 Jun 1993, Berlin; 1992.Google Scholar
  204. 204.
    National Alliance of State and Territorial AIDS Directors. Technical assistance and capacity building assistance for minority communities: a report from the NASTAD STATUS Project. Washington, DC: National Alliance of State and Territorial AIDS Directors; 2001. p. 1–30.Google Scholar
  205. 205.
    American Psychological Association. Behavioral science expertise needed for HIV prevention community planning. Psychology AIDS Exchange. 1996; 20:7.Google Scholar
  206. 206.
    Veniegas RC, Kao UH, Rosales R, Arellanes M. HIV prevention technology transfer: challenges and strategies in the real world. Am J Public Health. 2009;99:S124–30.PubMedCrossRefGoogle Scholar
  207. 207.
    Taveras S, Duncan T, Gentry D, Gilliam A, Kimbrough I, Minaya J. The evolution of the CDC HIV prevention capacity-building assistance initiative. J Public Health Manag Pract. 2007;13:S8–S15.Google Scholar
  208. 208.
    Miller RL, Bedney BJ, Guenther-Grey C. Assessing organizational capacity to deliver HIV prevention services collaboratively: tales from the field. Health Educ Behav. 2003;30:582–600.PubMedCrossRefGoogle Scholar
  209. 209.
    Kraft JM, Mezoff JS, Sogolow ED, Neumann MS, Thomas PA. A technology transfer model for effective HIV/AIDS interventions: science and practice. AIDS Educ Prev. 2000;12(Suppl A):7–20.PubMedGoogle Scholar
  210. 210.
    Richter DL, Potts LH, Prince MS, et al. Development of a curriculum to enhance community-based organizations’ capacity for effective HIV prevention programming and management. AIDS Educ Prev. 2006;18:362–74.PubMedCrossRefGoogle Scholar
  211. 211.
    Kelly JA, Somlai AM, DiFranceisco WJ, et al. Bridging the gap between the science and service of HIV prevention: transferring effective research-based HIV prevention interventions to community AIDS service providers. Am J Public Health. 2000;90:1082–8.PubMedCrossRefGoogle Scholar
  212. 212.
    Copenhaven MM, Fisher JD. Experts outline ways to decrease the decade-long yearly rate of 40,000 new HIV infections in the US. AIDS Behav. 2006;10:105–14.CrossRefGoogle Scholar
  213. 213.
    Valdiserri RO. Mapping the roots of HIV/AIDS complacency: implications for program and policy development. AIDS Educ Prev. 2004;16:426–39.PubMedCrossRefGoogle Scholar
  214. 214.
    Kaiser Family Foundation. 2009 Survey of Americans on HIV/AIDS: summary of findings on the domestic epidemic; 2009. http://www.kff.org/kaiserpolls/upload/7889.pdf. Accessed 5/11/09.
  215. 215.
    U.S. Census Bureau News. An Older and More Diverse Nation by Midcentury. August 14, 2008. Available at: http://www.census.gov/Press-Release/www/releases/archives/population/012496.html. Accessed on 12 May 2009.
  216. 216.
    Adimora AA, Schoenbach VJ, Doherty IA. Concurrent sexual partnerships among Men in the United States. Am J Public Health. 2007;97:2230–7.PubMedCrossRefGoogle Scholar
  217. 217.
    Adimora AA, Schoenbach VJ, Martinson FE, et al. Heterosexually transmitted HIV infection among African Americans in North Carolina. J Acquir Immune Defic Syndr. 2006;41:616–23.PubMedCrossRefGoogle Scholar
  218. 218.
    Adimora AA, Schoenbach VJ, Martinson F, Donaldson KH, Stancil TR, Fullilove RE. Concurrent sexual partnerships among African Americans in the rural south. Ann Epidemiol. 2004;14:155–60.PubMedCrossRefGoogle Scholar
  219. 219.
    Millett GA, Flores SA, Peterson JL, Bakeman R. Explaining disparities in HIV infection among Black and White men: a meta-analysis of HIV risk behaviors. AIDS. 2007;21:2083–91.PubMedCrossRefGoogle Scholar
  220. 220.
    Centers for Disease Control and Prevention. HIV infection among young Black men who have sex with men—Jackson, Mississippi, 2006–2008. MMWR Morb Mortal Wkly Rep. 2009;58:77–81.Google Scholar
  221. 221.
    Centers for Disease Control and Prevention. HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men—five U.S. cities, June 2004–April 2005. MMWR Morb Mortal Wkly Rep. 2005;54:597–601.Google Scholar
  222. 222.
    Laurencin CT, Christensen DM, Taylor ED. HIV/AIDS and the African American community: a state of emergency. J Natl Med Assoc. 2008;100:35–43.PubMedGoogle Scholar
  223. 223.
    Padian NS, Buve A, Balkus J, Serwadda D, Cates W. Biomedical interventions to prevent HIV infection: evidence, challenges, and the way forward. Lancet. 2008;372:585–99.PubMedCrossRefGoogle Scholar
  224. 224.
    Nuttal J, Romano J, Douville K, et al. The future of HIV prevention: prospects for an effective anti-HIV microbicide. Infect Dis Clin North Am. 2007;21:219–39.CrossRefGoogle Scholar
  225. 225.
    Cutler B, Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis. 2008;8:685–97.PubMedCrossRefGoogle Scholar
  226. 226.
    Siegfried N, Muller M, Deeks JJ, Volmink J. Male Circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev. 2009; 2:CD003362. Doi:  10.1002/14651858.CD003362.pub2.
  227. 227.
    Warner L, Ghanem KG, Newman DR, Macaluso M, Sullivan PS, Erbelding EJ. Male circumcision and risk of HIV infection among heterosexual African American men attending Baltimore sexually transmitted disease clinics. J Infect Dis. 2009;199:59–65.PubMedCrossRefGoogle Scholar
  228. 228.
    Leibowitz AA, Desmond K, Belin T. Determinants and policy implications of male circumcision in the United States. Am J Public Health. 2009;99:138–45.PubMedCrossRefGoogle Scholar
  229. 229.
    Smith DK, Taylor A, Kilmarx PH, et al. Male circumcision in the United States for the prevention of HIV infection and other adverse health outcomes: report from a CDC consultation. Public Health Rep. 2010;125 Suppl 1:72–82.PubMedGoogle Scholar
  230. 230.
    Centers for Disease Control and Prevention. HIV prevention through early detection and treatment of other sexually transmitted diseases—United States. MMWR Morb Mortal Wkly Rep. 1998;47(No. RR-12):1–24.Google Scholar
  231. 231.
    Rotheram-Borus MJ, Swendeman D, Chovnick G. The past, present and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol. 2009;5:143–67.PubMedCrossRefGoogle Scholar
  232. 232.
    Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med. 2008;358:1560–71.PubMedCrossRefGoogle Scholar
  233. 233.
    Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo controlled trial. Lancet. 1998;371:2109–19.CrossRefGoogle Scholar
  234. 234.
    White RG, Orroth KK, Glynn JR, et al. Treating curable sexually transmitted infections to prevent HIV in Africa. J Acquir Immune Defic Syndr. 2008;47:346–53.PubMedCrossRefGoogle Scholar
  235. 235.
    Centers for Disease Control and Prevention. CDC trials of pre-exposure prophylaxis for HIV prevention; 2009. http://www.cdc.gov/hiv/resources/Factsheets/print/prep.htm Accessed 19 May 2009.
  236. 236.
    Paxton LA, Hope T, Jaffe HW. Pre-exposure prophylaxis for HIV infection: what if it works? Lancet. 2007;370:89–93.PubMedCrossRefGoogle Scholar
  237. 237.
    Patiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48:806–15.CrossRefGoogle Scholar
  238. 238.
    Valdiserri RO. HIV/AIDS stigma: an impediment to public health. Am J Public Health. 2002;92:341–2.PubMedCrossRefGoogle Scholar
  239. 239.
    Mahajan AP, Sayles JN, Patel VA, et al. Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. AIDS. 2008;22 Suppl 2:S67–79.PubMedCrossRefGoogle Scholar
  240. 240.
    Kippax S, Holt M. The state of social and political science research related to HIV: a report for the International AIDS Society; 2009. http://www.iasociety.org.
  241. 241.
    Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342:921–9.PubMedCrossRefGoogle Scholar
  242. 242.
    Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS. 2004;18:81–8.PubMedCrossRefGoogle Scholar
  243. 243.
    Fang CT, Hsu HM, Twu SJ, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis. 2004;190:879–85.PubMedCrossRefGoogle Scholar
  244. 244.
    Clements MS, Prestage G, Grulich A, Van de Ven P, Kippax S, Law MG. Modeling trends in HIV incidence among homosexual men in Australia, 1995–2006. J Acquir Immune Defic Syndr. 2004;35:401–6.PubMedCrossRefGoogle Scholar
  245. 245.
    Castilla J, Romero J, Hernando V, Marincovich B, Garcia S, Rodriguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr. 2005;40:96–101.PubMedCrossRefGoogle Scholar
  246. 246.
    Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis. 2002;2:487–93.PubMedCrossRefGoogle Scholar
  247. 247.
    Granich R, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57.PubMedCrossRefGoogle Scholar
  248. 248.
    Vernazza P, Hirschel B, Bernasconi E, Flepp M. Les personnes seropositives ne souffrant d’aucune autre MST et suivant un traitment antirretroviral efficace ne transmettent pas le VIH par voie sexuelle. Bull Med Suisses. 2008;89:165–9.Google Scholar
  249. 249.
    Das-Douglas M, Chu P, Santos GM, et al. Decreases in community viral load are associated with a reduction in new HIV diagnoses in San Francisco. 17th conference on retroviruses and opportunistic infections; 2010. http://www.retroconference.org/2010/Abstracts/38232.htm. Accessed on 12 Mar 2010.
  250. 250.
    Montaner J, Wood E, Kerr T, et al. Association of expanded HAART coverage with a decrease in new HIV diagnoses, particularly among injection drug users in British Columbia, Canada. 17th conference on retroviruses and opportunistic infections; 2010. http://www.retroconference.org/2010/Abstracts/39866.htm. Accessed 12 Mar 2010.
  251. 251.
    Sheth P, Kovacs C, Kemal K, et al. Persistent HIV RNA shedding in semen despite effective ART. 16th Conference on retroviruses and opportunistic infections; 2009. http://www.retroconference.org/2009/Abstracts/35773.htm. Accessed 18 May 2009.
  252. 252.
    Marcelin AG, Tubiana R, Lambert-Niclot S, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. 16th conference on retroviruses and opportunistic infections; 2009. http://www.retroconference.org/2009/Abstracts/34040.htm. Accessed 18 May 2009.
  253. 253.
    Katz MH, Schwarcz SK, Kellog TA, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health. 2002;92:388–94.PubMedCrossRefGoogle Scholar
  254. 254.
    Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness. Lancet. 2008;372:314–20.PubMedCrossRefGoogle Scholar
  255. 255.
    Dieffenbach CW, Fauci A. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA. 2009;301:2380–2.PubMedCrossRefGoogle Scholar
  256. 256.
    Holtgrave DR. Strategies for preventing HIV transmission. JAMA. 2009;302:1530–1.PubMedCrossRefGoogle Scholar
  257. 257.
    Rekart ML, Patrick DM, Chakraborty B, et al. Targeted mass treatment for syphilis with oral azithromycin. Lancet. 2003;361:313–4.PubMedCrossRefGoogle Scholar
  258. 258.
    Pourbohloul B, Rekart M, Brunham RC. Impact of mass treatment on syphilis transmission: a mathematical model. Sex Transm Dis. 2003;30:297–305.PubMedCrossRefGoogle Scholar
  259. 259.
    Kerani RP, Handsfield HH, Stenger MS, et al. Rising rates of syphilis in the era of syphilis elimination. Sex Transm Dis. 2007;34:154–61.PubMedCrossRefGoogle Scholar
  260. 260.
    Hogben M, Leichliter JS. Social determinants and sexually transmitted disease disparities. Sex Transm Dis. 2008;35:S13–8.PubMedCrossRefGoogle Scholar
  261. 261.
    Francis DP, Anderson RE, Gorman ME, et al. Targeting AIDS prevention and treatment toward HIV-1-infected persons. JAMA. 1989;262:2572–6.PubMedCrossRefGoogle Scholar
  262. 262.
    Valdiserri RO, Holtgrave DR, West GR. Promoting early diagnosis and entry into care. AIDS. 1999;13:2317–30.PubMedCrossRefGoogle Scholar
  263. 263.
    Panel on Antiretroviral Guidelines for Adults and Adolescent. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. Dec 1; 2009. p. 1–161. http://www.aidsinfo.nih.gov/ContentFiles/Adultand%20AdolescentGL.pdf. Accessed 11 Jan 2010.
  264. 264.
    Janssen RS, Holtgrave DR, Valdiserri RO, et al. The serostatus approach to fighting the HIV epidemic: prevention strategies for infected individuals. Am J Public Health. 2001;91:1019–24.PubMedCrossRefGoogle Scholar
  265. 265.
    Centers for Disease Control and Prevention. Advancing HIV prevention: new strategies for a changing epidemic—United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:329–32.Google Scholar
  266. 266.
    Weinhardt LS, Kelly JA, Brondino MJ, et al. HIV transmission risk behavior among men and women living with HIV in 4 cities in the United States. J Acquir Immune Defic Syndr. 2004;36:1057–66.PubMedCrossRefGoogle Scholar
  267. 267.
    Crepaz N, Lyles CM, Wolitski RJ, et al. Do prevention interventions reduce HIV risk behaviours among people living with HIV? a meta-analytic review of controlled trials. AIDS. 2006;20:143–57.PubMedCrossRefGoogle Scholar
  268. 268.
    Marks G, Crepaz N, Senterfitt W, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39:446–53.PubMedCrossRefGoogle Scholar
  269. 269.
    Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20:1447–50.PubMedCrossRefGoogle Scholar
  270. 270.
    Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Morb Mortal Wkly Rep. 2006;55(RR-14):1–17.Google Scholar
  271. 271.
    Burke RC, Sepkowitz KA, Bernstein KT, et al. Why don’t physicians test for HIV? a review of the US literature. AIDS. 2007;21:1617–24.PubMedCrossRefGoogle Scholar
  272. 272.
    Centers for Disease Control and Prevention. Persons tested for HIV—United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57:845–9.Google Scholar
  273. 273.
    Bartlett JG, Branson BM, Fenton K, Hauschild BC, Miller V, Mayer KH. Opt-out testing for human immunodeficiency virus in the United States: progress and challenges. JAMA. 2008;300:945–51.PubMedCrossRefGoogle Scholar
  274. 274.
    Yarnall KS, Pollak KI, Ostbye T, Krause KM, Michener L. Primary care: is there enough time for prevention? Am J Public Health. 2003;93:635–41.PubMedCrossRefGoogle Scholar
  275. 275.
    Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1–12.CrossRefGoogle Scholar
  276. 276.
    Centers for Disease Control and Prevention. Incorporating HIV prevention into the medical care of persons living with HIV: Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep. 2003;52(No. RR-12):1–24.Google Scholar
  277. 277.
    Thrun M, Cook PF, Bradley-Springer LA, et al. Improved prevention counseling by HIV care providers in a multisite, clinic-based intervention: positive steps. AIDS Educ Prev. 2009;21:55–66.PubMedCrossRefGoogle Scholar
  278. 278.
    Buffardi AL, Thomas KK, Holmes KK, Manhart LE. Moving upstream: ecosocial and psychosocial correlates of sexually transmitted infections among young adults in the United States. Am J Public Health. 2008;98:1128–36.PubMedCrossRefGoogle Scholar
  279. 279.
    Valdiserri RO. Sexually transmitted infections among Gay and bisexual men. In: Wolitski R, Stall R, Valdiserri RO, editors. Unequal opportunity: health disparities affecting Gay and bisexual men in the United States. Oxford, England: Oxford University Press; 2008. p. 159–93.Google Scholar
  280. 280.
    Stall R, Mills TC, Williamson J, et al. Association of co-occuring psychosocial health problems and increased vulnerability to HIV/AIDS among urban men who have sex with men. Am J Public Health. 2003;93:939–42.PubMedCrossRefGoogle Scholar
  281. 281.
    Operario D, Smith CD, Kegeles S. Social and psychological context for HIV risk in non-Gay-identified African American men who have sex with men. AIDS Educ Prev. 2008;20:347–59.PubMedCrossRefGoogle Scholar
  282. 282.
    Neaigus A, Gyarmathy A, Miller M, Frajzyngier VM, Friedman SR, Des Jarlais DC. Transitions to injecting drug use among non-injecting heroin users: social network influence and individual susceptibility. J Acquir Immune Defic Syndr. 2006;41:493–503.PubMedCrossRefGoogle Scholar
  283. 283.
    Rich JA, Grey CM. Pathways to recurrent trauma among young Black men: traumatic stress, substance use, and the “Code of the Street”. Am J Public Health. 2005;95:816–24.PubMedCrossRefGoogle Scholar
  284. 284.
    Hooper S, Rosser BR, Horvath KJ, Oakes JM, Danilenko G. An online needs assessment of a virtual community: what men who use the internet to seek sex with men want in internet-based HIV prevention. AIDS Behav. 2008;12:867–75.PubMedCrossRefGoogle Scholar
  285. 285.
    Hightow L, Leone P, McCoy S, et al. Continued HIV transmission among African American MSM/W on North Carolina College Campuses: expanding sexual networks of internet use and crystal methamphetamine. 16th conference on retroviruses and opportunistic infections; 2009. http://www.retroconference.org/2009/Abstracts/26873.HTM. Accessed 20 May 2009.
  286. 286.
    Ellis RJ, Childers ME, Chemer M, Lazzaretto D, Letendre S, Grant I. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis. 2003;188:1820–6.PubMedCrossRefGoogle Scholar
  287. 287.
    Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep. 2005;2:194–9.PubMedCrossRefGoogle Scholar
  288. 288.
    Mansergh G, Purcell DW, Stall R, et al. CDC consultation on methamphetamine use and sexual risk behavior for HIV/STD infection: summary and suggestions. Public Health Rep. 2006;121:127–32.PubMedGoogle Scholar
  289. 289.
    Collins CV, Hearn KD, Whittier DN, Freeman A, Stallworth JD, Phields M. Implementing packaged HIV-prevention interventions for HIV positive individuals: considerations for clinic-based and community-based interventions. Public Health Rep. 2010;125 Suppl 1:55–63.PubMedGoogle Scholar
  290. 290.
    National Alliance of State and Territorial AIDS Directors and Kaiser Family Foundation. The National HIV Prevention Inventory: The State of HIV Prevention across the U.S.; 2009. http://www.kff.org/hivaids/prevention.cfm. Accessed 26 Feb 2010.

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.U.S. Department of Health and Human ServicesOffice of HIV/AIDS and Infectious Disease PolicyWashingtonUSA

Personalised recommendations